BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Annals of Hematology

Volumn 89, Issue 5, 2010, Pages 453-458

  Santamaría, Carlos ^a,b   Chillón, María C ^a   García Sanz, Ramón ^a,b   Pérez, Cristina ^c   Caballero, María D ^a   Mateos, María V ^a   Ramos, Fernando ^d   De Coca, Alfonso García ^e   Alonso, José M ^f   Giraldo, Pilar ^g   Bernal, Teresa ^h   Queizán, José A ⁱ   Rodríguez, Juan N ^j   Puig, Noemí ^a   Balanzategui, Ana ^a   Sarasquete, María E ^a   Alcoceba, Miguel ^a   Díaz Mediavilla, Joaquín ^c   San Miguel, Jesús ^a,b   González, Marcos ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f HOSPITAL RÍO CARRIÓN   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL GENERAL DE SEGOVIA   (Spain)

^j HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

more..

Author keywords

Acute myeloid leukemia; BAALC; Intermediate risk cytogenetics; Prognostic factor

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; ONCOPROTEIN; PROTEIN BAALC; PROTEIN EVI1; PROTEIN MN1; PROTEIN PRAME; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; WT1 PROTEIN; ANTINEOPLASTIC AGENT; BAALC PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; BIOSYNTHESIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950565905     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0864-x     Document Type: Article

References (19)

1. K Mrozek CD Bloomfield 2006 Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia Hematology 2006 169 177 10.1182/asheducation-2006.1.169
2. SM Tanner JL Austin G Leone LJ Rush C Plass K Heinonen K Mrozek H Sill S Knuutila JE Kolitz KJ Archer MA Caligiuri CD Bloomfield A de la Chapelle 2001 BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia Proc Natl Acad Sci USA 98 13901 13906 10.1073/pnas.241525498 1:CAS:528:DC%2BD3MXovVyntbo%3D 11707601 (Pubitemid 33115996)
3. CD Baldus SM Tanner AS Ruppert SP Whitman KJ Archer G Marcucci MA Caligiuri AJ Carroll JW Vardiman BL Powell SL Allen JO Moore RA Larson JE Kolitz A de la Chapelle CD Bloomfield 2003 BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study Blood 102 1613 1618 10.1182/blood-2003-02-0359 1:CAS:528:DC%2BD3sXntFartb0%3D 12750167 (Pubitemid 37022550)
4. CD Baldus C Thiede S Soucek CD Bloomfield E Thiel G Ehninger 2006 BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications J Clin Oncol 24 790 797 10.1200/JCO.2005.01.6253 1:CAS:528:DC%2BD28XitVGitr0%3D 16418499 (Pubitemid 46622046)
5. C Langer MD Radmacher AS Ruppert SP Whitman P Paschka K Mrozek CD Baldus T Vukosavljevic CG Liu ME Ross BL Powell A de la Chapelle JE Kolitz RA Larson G Marcucci CD Bloomfield 2008 High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood 111 5371 5379 10.1182/blood-2007-11-124958 1:CAS:528:DC%2BD1cXntFWns7g%3D 18378853
6. M Bienz M Ludwig EO Leibundgut BU Mueller D Ratschiller M Solenthaler MF Fey T Pabst 2005 Risk assessment in patients with acute myeloid leukemia and a normal karyotype Clin Cancer Res 11 1416 1424 10.1158/1078-0432.CCR-04-1552 1:CAS:528:DC%2BD2MXhvVSrsLo%3D 15746041 (Pubitemid 40315221)
7. C Langer G Marcucci KB Holland MD Radmacher K Maharry P Paschka SP Whitman K Mrozek CD Baldus R Vij BL Powell AJ Carroll JE Kolitz MA Caligiuri RA Larson CD Bloomfield 2009 Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study J Clin Oncol 27 3198 3204 10.1200/JCO.2008.20.6110 1:CAS:528: DC%2BD1MXhtFWitbrN 19451432
8. G Marcucci K Maharry SP Whitman T Vukosavljevic P Paschka C Langer K Mrozek CD Baldus AJ Carroll BL Powell JE Kolitz RA Larson CD Bloomfield 2007 High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J Clin Oncol 25 3337 3343 10.1200/JCO.2007.10.8720 1:CAS:528:DC%2BD2sXhtVWqs7jJ 17577018 (Pubitemid 47325620)
9. P Paschka G Marcucci AS Ruppert SP Whitman K Mrozek K Maharry C Langer CD Baldus W Zhao BL Powell MR Baer AJ Carroll MA Caligiuri JE Kolitz RA Larson CD Bloomfield 2008 Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study J Clin Oncol 26 4595 4602 10.1200/JCO.2007.15.2058 1:CAS:528:DC%2BD1cXht1KqtLfJ 18559874
10. DA Breems WL van Putten GE de Greef SL Van Zelderen-Bhola KB Gerssen-Schoorl CH Mellink A Nieuwint M Jotterand A Hagemeijer HB Beverloo B Lowenberg 2008 Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype J Clin Oncol 26 4791 4797 10.1200/JCO.2008.16.0259 18695255
11. CM Santamaria MC Chillon R Garcia-Sanz C Perez MD Caballero F Ramos AG de Coca JM Alonso P Giraldo T Bernal JA Queizan JN Rodriguez P Fernandez-Abellan A Barez MJ Penarrubia A Balanzategui MB Vidriales ME Sarasquete M Alcoceba J az-Mediavilla JF San Miguel M Gonzalez 2009 Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia Blood 114 148 152 10.1182/blood-2008-11-187724 1:CAS:528:DC%2BD1MXhtVOkurvP 19398719
12. J Krauter K Wagner I Schafer R Marschalek C Meyer G Heil M Schaich G Ehninger D Niederwieser R Krahl T Buchner C Sauerland B Schlegelberger K Dohner H Dohner RF Schlenk A Ganser 2009 Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup J Clin Oncol 27 3000 3006 10.1200/JCO.2008.16.7981 19380453
13. K Mrozek K Heinonen D Lawrence AJ Carroll PR Koduru KW Rao MP Strout RE Hutchison JO Moore RJ Mayer CA Schiffer CD Bloomfield 1997 Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study Blood 90 4532 4538 1:CAS:528:DyaK2sXnslWls70%3D 9373264
14. L Suarez MB Vidriales MJ Moreno A Lopez J Garcia-Larana C Perez-Lopez M Tormo E Lavilla MC Lopez-Berges M de Santiago JF San Miguel A Orfao 2005 Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells Haematologica 90 54 59 1:CAS:528:DC%2BD2MXhvFGjsLg%3D 15642669
15. A Oriol JM Ribera J Esteve R Guardia S Brunet J Bueno C Pedro A Llorente M Tormo J Besalduch JM Sanchez M Batlle P Vivancos E Carreras JM Vila A Julia J Sierra E Montserrat E Feliu 2004 Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol Haematologica 89 791 800 1:CAS:528:DC%2BD2cXnsFSms7k%3D 15257930
16. MC Chillon C Fernandez R Garcia-Sanz A Balanzategui F Ramos J Fernandez-Calvo M Gonzalez JF Miguel 2004 FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor Hematol J 5 239 246 10.1038/sj.thj.6200382 1:CAS:528:DC%2BD2cXksVajtbo%3D 15167911 (Pubitemid 38931330)
17. S Schnittger C Schoch W Kern C Mecucci C Tschulik MF Martelli T Haferlach W Hiddemann B Falini 2005 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 3733 3739 10.1182/blood-2005-06-2248 1:CAS:528:DC%2BD2MXht12ksbjJ 16076867 (Pubitemid 41739006)
18. C Santamaria MC Chillon R Garcia-Sanz A Balanzategui ME Sarasquete M Alcoceba F Ramos T Bernal JA Queizan MJ Penarrubia P Giraldo JF San Miguel M Gonzalez 2008 The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia Haematologica 93 1797 1805 10.3324/haematol.13214 18815192
19. J Gabert E Beillard V van der Velden W Bi D Grimwade N Pallisgaard G Barbany G Cazzaniga JM Cayuela H Cave F Pane JL Aerts D De Micheli X Thirion V Pradel M Gonzalez S Viehmann M Malec G Saglio JJ van Dongen 2003 Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program Leukemia 17 2318 2357 10.1038/sj.leu.2403135 1:CAS:528:DC%2BD3sXps12itL0%3D 14562125 (Pubitemid 38072573)